Literature DB >> 18771958

Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis.

Hsing-Hui Li1, He-Hsiung Cheng, Kuang-Hui Sun, Chi-Chen Wei, Chien-Feng Li, Wen-Chung Chen, Wen-Mein Wu, Ming-Shi Chang.   

Abstract

Lupus nephritis is one manifestation of systemic lupus erythematosus (SLE). Interleukin (IL)-10 is involved in the pathogenesis of SLE. To determine whether IL-20, a member of the IL-10 family, is associated with lupus nephritis, we analyzed the expression of IL-20 and its receptors in mesangial cells derived from SLE-prone, NZB/W, and DBA/W mice. IL-20 and its receptors were upregulated in mesangial cells from NZB/W mice. Incubating IL-20 with mesangial cells upregulated the transcripts of CCL2 (MCP-1), CCL5 (RANTES), CXCL10 (IP-10), IL-6, iNOS, and ROS, all of which are involved in the pathogenesis of lupus nephritis. IL-20 specifically activated the downstream signal ERK 1/2. We also detected human IL-20 protein in both mesangial cells and inflammatory cells in kidney biopsies of patients with lupus nephritis. Our results reveal the novel effects of IL-20 on mesangial cells and its association with lupus nephritis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18771958     DOI: 10.1016/j.clim.2008.07.006

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  13 in total

1.  A polymorphism of interleukin-22 receptor alpha-1 is associated with the development of childhood IgA nephropathy.

Authors:  Jin-Soon Suh; Seong H Cho; Joo-Ho Chung; Ahrim Moon; Yong-Koo Park; Byoung-Soo Cho
Journal:  J Interferon Cytokine Res       Date:  2013-05-09       Impact factor: 2.607

Review 2.  IL-20 receptor cytokines in autoimmune diseases.

Authors:  Jun Chen; Rachel R Caspi; Wai Po Chong
Journal:  J Leukoc Biol       Date:  2018-09-07       Impact factor: 4.962

3.  Expressions of IL-22 in circulating CD4+/CD8+ T cells and their correlation with disease activity in SLE patients.

Authors:  Wei-Zi Qin; Li-Li Chen; Hai-Feng Pan; Rui-Xue Leng; Zhi-Min Zhai; Chao Wang; Ruo-Jie Li; Song Wang; Hui-Ping Wang; Dong-Qing Ye
Journal:  Clin Exp Med       Date:  2011-04-13       Impact factor: 3.984

Review 4.  The biology of reactive intermediates in systemic lupus erythematosus.

Authors:  Jim C Oates
Journal:  Autoimmunity       Date:  2010-02       Impact factor: 2.815

5.  IL-10-- and IL-20--expressing epithelial and inflammatory cells are increased in patients with ulcerative colitis.

Authors:  Gabriela Fonseca-Camarillo; Janette Furuzawa-Carballeda; Luis Llorente; Jesús K Yamamoto-Furusho
Journal:  J Clin Immunol       Date:  2012-12-04       Impact factor: 8.317

6.  Decreased interleukin-20 expression in scleroderma skin contributes to cutaneous fibrosis.

Authors:  Hideo Kudo; Masatoshi Jinnin; Yoshihide Asano; Maria Trojanowska; Wakana Nakayama; Kuniko Inoue; Noritoshi Honda; Ikko Kajihara; Katsunari Makino; Satoshi Fukushima; Hironobu Ihn
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

7.  Changes in inflammatory cytokine networks in myasthenia gravis.

Authors:  Akiyuki Uzawa; Tetsuya Kanai; Naoki Kawaguchi; Fumiko Oda; Keiichi Himuro; Satoshi Kuwabara
Journal:  Sci Rep       Date:  2016-05-13       Impact factor: 4.379

8.  Interleukin-20 targets podocytes and is upregulated in experimental murine diabetic nephropathy.

Authors:  Yu-Hsiang Hsu; Hsing-Hui Li; Junne-Ming Sung; Wei-Yu Chen; Ya-Chin Hou; Yun-Han Weng; Wei-Ting Lai; Chih-Hsing Wu; Ming-Shi Chang
Journal:  Exp Mol Med       Date:  2017-03-31       Impact factor: 8.718

9.  Anti-IL-20 antibody improved motor function and reduced glial scar formation after traumatic spinal cord injury in rats.

Authors:  Jung-Shun Lee; Yu-Hsiang Hsu; Yi-Shu Chiu; I-Ming Jou; Ming-Shi Chang
Journal:  J Neuroinflammation       Date:  2020-05-14       Impact factor: 8.322

10.  Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment.

Authors:  Maria C Lebre; Christina L Jonckheere; Maarten C Kraan; Arno W R van Kuijk; Jan D Bos; Menno de Rie; Danielle M Gerlag; Paul P Tak
Journal:  Arthritis Res Ther       Date:  2012-09-24       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.